中源协和(600645.SH)子公司VUM02注射液获批临床试验

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of VUM02 injection for the treatment of severe/critical pneumonia [1] Group 1 - VUM02 injection is an autologous developed cryopreserved cell preparation derived from selected healthy newborn umbilical cord tissue [1] - The clinical indication for VUM02 injection is being expanded to include the treatment of severe/critical pneumonia [1]